Document is current
Any future updates will be listed below
-
Authors
Santos, Joao
Svane, Inge
Peltola, Katriina
Alanko, Tuomo
Korpisaari, Riitta
Juteau, Susanna
Jaakkola, Marjut
Sormunen, Jorma
Kononen, Juha
Ellebaek, Eva
Monberg, Tine
Donia, Marco
Khammari, Amir
Dreno, Brigitte
Pakola, Santeri A
Clubb, James
Jirovec, Elise
Quixabeira, Dafne CA
Kudling, Tatiana
Haybout, Lyna
Cervera-Carrascon, Victor
Kistler, Claudia
Sorsa, Suvi
Havunen, Riikka
Hemminki, Akseli
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04695327 at ClinicalTrials.govnct04217473 at ClinicalTrials.govDocuments that mention this clinical trial
739 Emerging proteomic and safety analysis of blood from solid tumor patients receiving TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2) monotherapy in TUNIMO phase 1 clinical trial
https://doi.org/10.1136/jitc-2023-sitc2023.0739
749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors – Interim results
https://doi.org/10.1136/jitc-2023-sitc2023.0749
715 Emerging results from the use of an oncolytic adenovirus armed with TNFa and IL-2 (TILT-123) in different phase I solid tumor clinical trials
https://doi.org/10.1136/jitc-2022-sitc2022.0715
745 Immune cell profiling of advanced-stage solid tumors patients treated with an oncolytic adenovirus encoding for TNF-a and IL-2 (TILT-123)
https://doi.org/10.1136/jitc-2023-sitc2023.0745
711 Development of oncolytic adenovirus Ad5/3-E2F-D24-hTNFa-IRES-hIL2 (TILT-123) for the treatment of solid tumours – from preclinical testing to phase I clinical trials
https://doi.org/10.1136/jitc-2023-sitc2023.0711
1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)
https://doi.org/10.1136/jitc-2023-sitc2023.1518
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial
https://doi.org/10.1136/jitc-2024-010493
nct05271318 at ClinicalTrials.govDocuments that mention this clinical trial
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies
https://doi.org/10.1136/jitc-2021-002555
514 Biomarker insights and long-term outcomes of TILT-123 oncolytic adenovirus combined with tumor-infiltrating lymphocytes in refractory metastatic melanoma: results from the TUNINTIL phase 1 trial
https://doi.org/10.1136/jitc-2025-sitc2025.0514
749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors – Interim results
https://doi.org/10.1136/jitc-2023-sitc2023.0749
715 Emerging results from the use of an oncolytic adenovirus armed with TNFa and IL-2 (TILT-123) in different phase I solid tumor clinical trials
https://doi.org/10.1136/jitc-2022-sitc2022.0715
1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)
https://doi.org/10.1136/jitc-2023-sitc2023.1518
nct05222932 at ClinicalTrials.govDocuments that mention this clinical trial
PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer.
https://doi.org/10.1200/jco.2024.42.16_suppl.5562
749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors – Interim results
https://doi.org/10.1136/jitc-2023-sitc2023.0749
715 Emerging results from the use of an oncolytic adenovirus armed with TNFa and IL-2 (TILT-123) in different phase I solid tumor clinical trials
https://doi.org/10.1136/jitc-2022-sitc2022.0715
1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)
https://doi.org/10.1136/jitc-2023-sitc2023.1518
Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?
https://doi.org/10.1136/jitc-2022-006518
nct04695327 at ClinicalTrials.govDocuments that mention this clinical trial
749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors – Interim results
https://doi.org/10.1136/jitc-2023-sitc2023.0749
715 Emerging results from the use of an oncolytic adenovirus armed with TNFa and IL-2 (TILT-123) in different phase I solid tumor clinical trials
https://doi.org/10.1136/jitc-2022-sitc2022.0715
1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)
https://doi.org/10.1136/jitc-2023-sitc2023.1518
Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?
https://doi.org/10.1136/jitc-2022-006518
nct04217473 at ClinicalTrials.govDocuments that mention this clinical trial
739 Emerging proteomic and safety analysis of blood from solid tumor patients receiving TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2) monotherapy in TUNIMO phase 1 clinical trial
https://doi.org/10.1136/jitc-2023-sitc2023.0739
749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors – Interim results
https://doi.org/10.1136/jitc-2023-sitc2023.0749
715 Emerging results from the use of an oncolytic adenovirus armed with TNFa and IL-2 (TILT-123) in different phase I solid tumor clinical trials
https://doi.org/10.1136/jitc-2022-sitc2022.0715
745 Immune cell profiling of advanced-stage solid tumors patients treated with an oncolytic adenovirus encoding for TNF-a and IL-2 (TILT-123)
https://doi.org/10.1136/jitc-2023-sitc2023.0745
711 Development of oncolytic adenovirus Ad5/3-E2F-D24-hTNFa-IRES-hIL2 (TILT-123) for the treatment of solid tumours – from preclinical testing to phase I clinical trials
https://doi.org/10.1136/jitc-2023-sitc2023.0711
1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)
https://doi.org/10.1136/jitc-2023-sitc2023.1518
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial
https://doi.org/10.1136/jitc-2024-010493
nct05271318 at ClinicalTrials.govDocuments that mention this clinical trial
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies
https://doi.org/10.1136/jitc-2021-002555
514 Biomarker insights and long-term outcomes of TILT-123 oncolytic adenovirus combined with tumor-infiltrating lymphocytes in refractory metastatic melanoma: results from the TUNINTIL phase 1 trial
https://doi.org/10.1136/jitc-2025-sitc2025.0514
749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors – Interim results
https://doi.org/10.1136/jitc-2023-sitc2023.0749
715 Emerging results from the use of an oncolytic adenovirus armed with TNFa and IL-2 (TILT-123) in different phase I solid tumor clinical trials
https://doi.org/10.1136/jitc-2022-sitc2022.0715
1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)
https://doi.org/10.1136/jitc-2023-sitc2023.1518
nct05222932 at ClinicalTrials.govDocuments that mention this clinical trial
PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer.
https://doi.org/10.1200/jco.2024.42.16_suppl.5562
749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors – Interim results
https://doi.org/10.1136/jitc-2023-sitc2023.0749
715 Emerging results from the use of an oncolytic adenovirus armed with TNFa and IL-2 (TILT-123) in different phase I solid tumor clinical trials
https://doi.org/10.1136/jitc-2022-sitc2022.0715
1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)
https://doi.org/10.1136/jitc-2023-sitc2023.1518
Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?
https://doi.org/10.1136/jitc-2022-006518
Documents that mention this clinical trial
749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors – Interim results
https://doi.org/10.1136/jitc-2023-sitc2023.0749
715 Emerging results from the use of an oncolytic adenovirus armed with TNFa and IL-2 (TILT-123) in different phase I solid tumor clinical trials
https://doi.org/10.1136/jitc-2022-sitc2022.0715
1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)
https://doi.org/10.1136/jitc-2023-sitc2023.1518
Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?
https://doi.org/10.1136/jitc-2022-006518
- License Information
